Nemera acquired by Montagu Private Equity
Context
The deal involves the carve-out of Rexam's healthcare devices and prescription retail divisions, which will be acquired by Montagu Private Equity. The transaction is subject to regulatory approval and is expected to be completed in the coming weeks. The strategic rationale behind the deal is to create a standalone company that can focus on the healthcare sector and leverage Montagu Private Equity's expertise and resources to drive growth and expansion. The deal is expected to enhance the competitiveness of the company and improve its market position, while also providing opportunities for innovation and investment in new products and technologies. The company's management team will work closely with Montagu Private Equity to develop a growth strategy that builds on the company's strengths and addresses the evolving needs of the healthcare market. With a strong foundation in place, the company is well-positioned to capitalize on emerging trends and opportunities in the healthcare sector, including the growing demand for innovative medical devices and pharmaceutical packaging solutions.
Nemera, which reported an EBITDA margin of [members only] in 2013, is valued in this transaction at an EV/EBITDA multiple of 5x–12x.
-> Deep-dive in Healthcare & Pharma market trends
Target
Nemera (ex Rexam Healthcare Devices and Prescription Retail) is a leading provider of healthcare devices and pharmaceutical packaging solutions. The company's healthcare devices division designs and manufactures a range of products, including inhalers for asthma, insulin pens, and nasal pumps. The prescription retail division produces flacons and security caps for medications sold in pharmacies. With a strong presence in Europe and the United States, the company has a diverse portfolio of products that cater to various healthcare markets, including pulmonary, parenteral, ENT, dermal, and ophthalmic. The company's products are designed to improve patient outcomes and enhance the overall quality of healthcare. With a rich history and a strong commitment to innovation, Rexam Healthcare Devices and Prescription Retail has established itself as a trusted partner in the healthcare industry.
Ent. Value
€500M–1.5bn
Equity Value
[members only]
Multiples
EV / Revenue
1x–3x
EV / EBITDA
5x–12x
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with Nemera
Other operations with Montagu Private Equity
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 12/2025 | MONTAGU PRIVATE EQUITY / KOHLBERG | TELEFLEX MEDICAL OEM | UNITED STATES | Medical Consumables |
| 06/2025 | MONTAGU PRIVATE EQUITY | MULTIFONDS | LUXEMBOURG | Financial Services / Banking |
| 05/2023 | TA ASSOCIATES / MONTAGU PRIVATE EQUITY | HARVEST | FRANCE | Financial Services / Banking |
| 02/2022 | MONTAGU PRIVATE EQUITY / PARTNERS GROUP | HTL BIOTECHNOLOGY | FRANCE | CDMO |
| 07/2021 | MONTAGU PRIVATE EQUITY | INTECH MEDICAL | FRANCE | Implants & Prosthetics |
| 01/2021 | MONTAGU PRIVATE EQUITY | IMV TECHNOLOGIES | FRANCE | R&D Biotech |
| 03/2020 | TETHYS INVEST / CPPIB (CANADA PENSION PLAN INVESTMENT BOARD) / MONTAGU PRIVATE EQUITY | GALILEO GLOBAL EDUCATION | FRANCE | Education Providers |
| 06/2017 | HG CAPITAL / GIC / MONTAGU PRIVATE EQUITY / ICG | VISMA GROUP | NORWAY | ERP, HR & Finance |
| 03/2014 | MONTAGU PRIVATE EQUITY | ARKOPHARMA | FRANCE | Nutrition & Dietary Supplements |
| 06/2009 | MONTAGU PRIVATE EQUITY | ADB SAFEGATE | BELGIUM | Aerospace, Naval & Defense |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 09/2014 | INSTITUT MERIEUX / SAGARD / SOFIPROTEOL | CEVA SANTE ANIMALE | FRANCE | Animal Health |
| 03/2014 | MONTAGU PRIVATE EQUITY | ARKOPHARMA | FRANCE | Nutrition & Dietary Supplements |
| 01/2014 | FIVE ARROWS | DUTSCHER | FRANCE | Medical Consumables |
| 10/2013 | ARDIAN | LABORATOIRES ANIOS | FRANCE | Medical Consumables |
| 07/2013 | CHARTERHOUSE | DOC GENERICI | ITALY | Generics / Labs |
| 06/2013 | BC PARTNERS | ANTELLIQ | FRANCE | Animal Health |
| 06/2013 | EURAZEO | PÉTERS SURGICAL | FRANCE | Medical Consumables |
| 01/2013 | ELITECH GROUP | VITAL DIAGNOSTICS | UNITED STATES | Diagnostic Equipment |
| 08/2012 | BC PARTNERS | AENOVA GROUP | GERMANY | CDMO |
| 05/2011 | AZULIS CAPITAL / BNP PARIBAS DEVELOPPEMENT / GALIA | LAGARRIGUE | FRANCE | Implants & Prosthetics |
REFERENCES
Valuation range: EV €500M–1.5bn
Revenue range: €250–500M
EBITDA range: €50–100M
EV/Revenue range: 1x - 3x
EV/EBITDA range: 5x - 12x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Nemera by Montagu Private Equity are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: nemera
FAQ
What transaction does this page cover?
How was the acquisition of Nemera by Montagu Private Equity valued, and what multiples were paid?
What were Nemera’s revenue and EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?